LO31 logo

Lonza Group DB:LO31 Stock Report

Last Price

€5.60

Market Cap

€42.1b

7D

n/a

1Y

n/a

Updated

17 Mar, 2025

Data

Company Financials +

LO31 Stock Overview

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details

LO31 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends3/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Lonza Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lonza Group
Historical stock prices
Current Share PriceCHF 5.60
52 Week HighCHF 5.80
52 Week LowCHF 5.60
Beta0.68
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-3.45%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

LO31DE Life SciencesDE Market
7Dn/a3.1%1.6%
1Yn/a-13.3%16.4%

Return vs Industry: Insufficient data to determine how LO31 performed against the German Life Sciences industry.

Return vs Market: Insufficient data to determine how LO31 performed against the German Market.

Price Volatility

Is LO31's price volatile compared to industry and market?
LO31 volatility
LO31 Average Weekly Movementn/a
Life Sciences Industry Average Movement7.0%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: LO31's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine LO31's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
189718,686Wolfgang Wienandwww.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.

Lonza Group AG Fundamentals Summary

How do Lonza Group's earnings and revenue compare to its market cap?
LO31 fundamental statistics
Market cap€42.07b
Earnings (TTM)€661.50m
Revenue (TTM)€6.84b

63.6x

P/E Ratio

6.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LO31 income statement (TTM)
RevenueCHF 6.57b
Cost of RevenueCHF 4.16b
Gross ProfitCHF 2.41b
Other ExpensesCHF 1.78b
EarningsCHF 636.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 03, 2025

Earnings per share (EPS)8.81
Gross Margin36.67%
Net Profit Margin9.67%
Debt/Equity Ratio50.2%

How did LO31 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

45%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 11:06
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lonza Group AG is covered by 47 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Charles Pitman-KingBarclays
Sebastian BrayBerenberg